Lenalidomida Tecnigen (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, which leads to the selective degradation of transcription factors Ikaros and Aiolos. This action modifies cytokine production, enhances immune‑cell activity, inhibits new blood‑vessel formation, and triggers anti‑proliferative and pro‑apoptotic pathways in malignant cells.

The specific dose of Lenalidomida Tecnigen is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal and hepatic function, and prior therapies. Dosage regimens are individualized and should follow the latest clinical guidelines and the product’s prescribing information.

Lenalidomida Tecnigen is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while receiving the drug.

To order Lenalidomida Tecnigen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lenalidomide is a second‑generation immunomodulatory agent, structurally related to thalidomide but with greater potency and a more favorable safety profile. Compared with thalidomide, lenalidomide has reduced neurotoxicity, a lower incidence of constipation, and stronger anti‑angiogenic activity, making it a preferred option for many hematologic indications.

Store Lenalidomida Tecnigen at below 25 °C in its original packaging, protected from moisture and light. Keep the product out of reach of children and avoid crushing or splitting tablets unless specifically instructed by a pharmacist.

Lenalidomida Tecnigen is administered orally, usually once daily on a prescribed schedule that may include treatment cycles with rest periods. The tablet should be swallowed whole with water and taken at the same time each day, unless the prescribing clinician advises otherwise.

Serious risks include venous thromboembolism, severe cutaneous reactions such as Stevens‑Johnson syndrome, secondary primary malignancies, and significant liver toxicity. Patients should be monitored regularly for signs of blood clots, skin changes, abnormal liver function tests, and new cancer development.

Lenalidomida Tecnigen should not be used by pregnant women, individuals with uncontrolled infections, patients with severe hepatic impairment without close monitoring, or anyone with a known hypersensitivity to lenalidomide or its excipients. It is also contraindicated in patients receiving live vaccines during therapy.